Global Actinic Keratosis Treatment Market Insights Forecasts to 2032

• The Global Actinic Keratosis Treatment Market Size was valued at USD 5.5 Billion in 2022.
• The Market Size is Growing at a CAGR of 5.8% from 2022 to 2032.
• The Worldwide Actinic Keratosis Treatment Market size is expected to reach USD 9.7 Billion by 2032.
• Asia Pacific is expected To Grow the fastest during the forecast period.

 

Get more details on this report -

Request Free Sample PDF

 

The Global Actinic Keratosis Treatment Market Size is expected to reach USD 9.7 Billion by 2032, at a CAGR of 5.8% during the forecast period 2022 to 2032.

 

Market Overview

Actinic Keratosis is a skin injury caused by overexposure to the sun. Actinic keratosis is a common precursor of skin cancer. Actinic keratosis is a chronic disorder in which the majority of patients experience reoccurring lesions throughout time. Actinic keratosis raises the risk of skin cancer because it can progress to squamous cell carcinoma (SCC), a common and sometimes invasive skin cancer. Squamous cell carcinoma, a malignant skin tumor that arises from keratinizing cells (keratinocytes) in the epidermis or skin adnexa, is an early precursor of actinic keratosis. Treatment is often suggested because of the potential that actinic keratosis will progress to SCC. Cryotherapy, photodynamic treatment, or topical medicines are commonly used to treat the illness. Increasing consumer awareness of dermatological conditions such as actinic keratosis is a significant growth driver for the market. The increased understanding of diagnoses and treatment techniques for this illness has resulted in the widespread use of actinic keratosis drugs. Also, Field-directed therapies such as 5-fluorouracil, diclofenac, Ingenol mebutate, and Imiquimod are expected to gain market share in the next years.

 

Report Coverage

This research report categorizes the global actinic keratosis treatment market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global actinic keratosis treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global actinic keratosis treatment market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.

 

Driving Factors

One of the primary market drivers is the prevalence of actinic keratosis. Also, the growing elderly population throughout the globe is expected to drive market growth over the forecast period. According to AMERICA's HEALTH RANKINGS senior report 2021, it is predicted that more than 54 million individuals over the age of 65 live in the United States, accounting for 16.5% of the total population. Furthermore, Statista Canada estimates that there will be 6,835,866 persons over the age of 65 in July 2021, accounting for 18% of the overall population. Moreover, to improve their market share, key industry players are launching new products, forming alliances, and expanding their operations. For example, Almirall, S.A. announced in September 2021 the commercial introduction of Klisyri (tirbanibulin) in Germany and the United Kingdom. The firm announced the launch of this medicine after getting clearance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Commission for the treatment of actinic keratosis of the scalp and face in adults.

 

Restraining Factors

Actinic keratosis (AK) treatment methods involve dangers and side effects that may limit the sector's growth. Topical medicines, cryotherapy, photodynamic therapy, and surgical removal all include hazards such as skin irritation, redness, itching, or pain at the treatment site. In addition, specific therapies may cause temporary skin discoloration, scarring, and infection. These possible adverse effects may influence patient satisfaction and treatment regimen adherence. Furthermore, the availability of alternative therapies such as generic medication, as well as over-the-counter and home cures, may restrict demand for prescription-based AK treatments.

 

Market Segmentation

• In 2022, the surgery segment is influencing the market with the largest market share over the forecast period.

Based on the therapy, the global actinic keratosis treatment market is segmented into topical, surgery, and photodynamic therapy. Among these segments, the surgery segment is dominating the market with the largest revenue share during the forecast period owing to better penetration of cryotherapy for the treatment of actinic keratosis. However, the topical therapy category is predicted to develop steadily due to rising self-use therapy usage, increasing home-based treatments, and different strategic initiatives undertaken by market participants.

 

• In 2022, the nucleoside segment is dominating the largest market share during the forecast period.

Based on the drug class, the global actinic keratosis treatment market is bifurcated into different categories such as nucleoside metabolic inhibitors, NSAIDs, immune response modifiers, photo enhancers & others. Among these segments, the nucleoside segment is dominating the market. The remarkable commercial performance of Efudex, Carac, and Fluroplex is credited with the emergence of nucleoside metabolic inhibitors. Furthermore, growing awareness of actinic keratosis therapy and diagnosis has propelled the segment's rise. The expansion of the nucleoside metabolic inhibitors segment is further aided by several strategic efforts undertaken by industry participants.

 

• In 2022, the hospitals segment is dominating the largest market share over the forecast period.

Based on the end user, the global actinic keratosis treatment market is classified into hospitals, private clinics, Homecare & others. Among these segments, hospitals are dominating the market. This is due to variables such as treatment rate accessibility, healthcare facility availability, and the increasing number of photodynamic therapy treatments conducted in hospitals. Photodynamic treatment is performed using a variety of prescription medications. LEVULAN and KERASTICK are prescription medications developed by DUSA Pharmaceuticals, Inc. that are used on the skin using blue light therapy (PDT) to treat mild to moderately thick actinic keratosis of the head, upper arms, and face.

 

The homecare segment is expected to register the fastest growth rate over the forecast period due to the increasing popularity of topical products, patient convenience considerations, the availability of OTC products, and the increased launch of topical products are all contributing to the growth of the homecare market. The greater availability of topical treatments has raised demand in the homecare industry.

 

Regional Segment Analysis of the actinic keratosis treatment market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America dominated the market with the largest market revenue during the forecast period

 

Get more details on this report -

Request Free Sample PDF

 

North America is leading the significant market growth over the forecast period due to the increased prevalence of actinic keratosis, positive government measures, rising consumer awareness, improvements in healthcare infrastructure, and continued technology breakthroughs are ascribed to the growth. The presence of significant market players in North America is also one of the important factors driving industry expansion. Furthermore, favorable government efforts and reimbursement rules are projected to enhance sector growth.

 

Asia Pacific is expected to experience high revenue market growth during the forecast period due to Increased treatment adoption, growing consumer disposable income, and high illness incidence in some countries, such as Australia and New Zealand, which are among the main drivers driving the market over the projection period.

 

Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the global actinic keratosis treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Almirall S.A.
• LEO Pharma A/S
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• GALDERMA
• Ortho Dermatologics (Bausch Health Companies Inc.)
• BIOFRONTERA AG
• Hill Dermaceuticals, Inc.

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In December 2022, AMELUZ was commercially released in Finland by Biofrontera AG. This product launch conforms to European clearance for the treatment of actinic keratoses and basal cell carcinoma using the BF-RhodoLED lamp as part of traditional photodynamic therapy or as daylight therapy. This strategy assisted the corporation in improving its product offerings as well as strengthening its geographical footprint in Europe.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Actinic Keratosis Treatment Market based on the below-mentioned segments:

 

Global Actinic Keratosis Treatment Market, By Therapy

• Topical
• Surgery
• Photodynamic Therapy

 

Global Actinic Keratosis Treatment Market, By Drug Class

• Nucleoside Metabolic Inhibitor
• NSAIDs
• Immune Response Modifiers
• Photoenhancers
• Others

 

Global Actinic Keratosis Treatment Market, By End Users

• Hospitals
• Private Clinics
• Homecare
• Others

 

Actinic Keratosis Treatment Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa